Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

"This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including ...